UNITED STATES: Relationships of Deterrence and Law Enforcement to Drug-Related Harms Among Drug Injectors in US Metropolitan Areas

Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.

UNITED STATES: Relationships of Deterrence and Law Enforcement to Drug-Related Harms Among Drug Injectors in US Metropolitan Areas

AIDS Vol. 20; No. 1: P. 93-99 (01.02.06) - Friday, December 16, 2005
Samuel R. Friedman; Hannah L.F. Cooper; Barbara Tempalski; Maria Keem; Risa Friedman; Peter L. Flom; Don C. Des Jarlais

To understand associations of punitive policies to the population prevalence of injection drug users (IDUs) and to HIV seroprevalence among IDUs, the authors conducted a lagged- cross-sectional analysis of US metropolitan statistical area data.

After controlling for other metropolitan area characteristics, estimates of IDUs per capita and HIV seroprevalence among IDUs in 89 large US metro areas were regressed on three measures of legal repressiveness (hard drug arrests per capita; police employees per capita; and corrections expenditures per capita).

The researchers found no legal repressiveness measures were associated with IDUs per capita. However, all three measures of legal repressiveness were positively associated with HIV prevalence among IDUs.

These findings suggest that legal repressiveness may have little deterrent on drug injection and may have a high cost in terms of HIV and perhaps other diseases among injectors and their partners - and that alternative methods of maintaining social order should be investigated, the authors concluded.
051216
AD052537

Copyright © 2005 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.